Abstract
A flurry of activity in the development and licensing of DTaP (diphtheria-tetanus-acellular pertussis) vaccines coincides with the Academy9s release of a related policy statement, recommending the use of acellular over the whole-cell vaccine (DTwP) for the initial series in infants and children. These events may bode well for DTaP9s potential use in adults and for the future availability of more combined vaccines. The most recent event came at the close of 1996, with licensure of the first DTaP product for use in all five doses in the DTP immunization series. Licensed by Wyeth-Leder-le Vaccines and Pediatrics, the use of Acel-Imune (Diptheria and Tetanus Toixoids and Acellular Pertussis Vaccine Adsorbed), has been expanded to include infants at 2, 4 and 6 months of age. Until now, Acel-Imune had been approved for booster use in the fourth and fifth doses in children who had received the whole-cell vaccine in the first three doses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
